Published in
American Society of Hematology, Blood, p. blood-2016-08-736066
DOI: 10.1182/blood-2016-08-736066
Links
Tools
HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies
Journal article published in 2017 by
Malgorzata Bobrowicz 
,
Michal Dwojak,
Beata Pyrzynska,
Joanna Stachura,
Angelika Muchowicz,
Elise Berthel,
Nicole Dalla-Venezia,
Mieszko Kozikowski,
Marta Siernicka,
Nina Miazek,
Piotr Zapala,
Antoni Domagala,
Kamil Bojarczuk,
Agata Malenda,
Joanna Barankiewicz
and other authors.
,
Michal Dwojak,
Beata Pyrzynska,
Joanna Stachura,
Angelika Muchowicz,
Elise Berthel,
Nicole Dalla-Venezia,
Mieszko Kozikowski,
Marta Siernicka,
Nina Miazek,
Piotr Zapala,
Antoni Domagala,
Kamil Bojarczuk,
Agata Malenda,
Joanna Barankiewicz
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points HDAC6 inhibition represents a novel strategy to improve the efficacy of anti-CD20 mAbs. HDAC6 inhibition increases CD20 levels by enhancing CD20 protein synthesis without affecting the gene expression.